Skip to main content

Table 1 Intensity of pain symptoms at baseline and during treatment

From: Letrozole and norethisterone acetate versus letrozole and triptorelin in the treatment of endometriosis related pain symptoms: a randomized controlled trial

  VAS scale Multidimensional categorical rating scale
  group T
(n = 18)
group N
(n = 17)
p group T
(n = 18)
group N
(n = 17)
p
Dysmenorrhea       
- baseline 8.7 ± 1.1
(n = 18)
8.6 ± 1.3
(n = 16)
0.881 3 (2-3)
(n = 18)
3 (0-3)
(n = 17)
0.890
Nonmenstrual pelvic pain       
- baseline 6.1 ± 1.4
(n = 16)
6.0 ± 1.4
(n = 14)
0.783 2 (0-3)
(n = 18)
2 (0-3)
(n = 17)
0.957
- 3 months of treatment 3.2 ± 1.3
(n = 15)
3.3 ± 1.5
(n = 14)
0.782 1 (0-2)
(n = 17)
1 (0-2)
(n = 17)
0.818
- 6 months of treatment 1.2 ± 1.3
(n = 9)
2.0 ± 1.8
(n = 14)
0.286 0 (0-2)
(n = 10)
1 (0-2)
(n = 16)
0.171
p value: 3 month of treatment vs baseline < 0.001 < 0.001   < 0.001 < 0.001  
p value: 6 month of treatment vs baseline < 0.001 < 0.001   0.004 < 0.001  
p value: 6 month of treatment vs 3 month 0.001 < 0.001   0.063 0.156  
Deep dyspareunia a       
- baseline 6.4 ± 1.9
(n = 12)
6.6 ± 2.1
(n = 14)
0.801 2 (0-3)
(n = 14)
2 (0-3)
(n = 15)
0.501
- 3 months of treatment 3.4 ± 1.2
(n = 11)
3.6 ± 1.5
(n = 14)
0.635 1 (0-2)
(n = 13)
1 (0-2)
(n = 15)
0.853
- 6 months of treatment 2.0 ± 0.9
(n = 4)
2.2 ± 1.4
(n = 13)
0.727 1 (0-1)
(n = 6)
1 (0-2)
(n = 14)
0.406
p value: 3 month of treatment vs baseline < 0.001 < 0.001   0.031 < 0.001  
p value: 6 month of treatment vs baseline 0.022 < 0.001   0.042 < 0.001  
p value: 6 month of treatment vs 3 month of treatment 0.088 < 0.001   0.076 0.125  
  1. a14 women included in group T and 15 women included in group N were sexually active at the time of the study
  2. The intensity of each pain symptom was measured only for patients suffering the symptom; the multidimensional categorical rating scale was calculated for all the patients because this scale includes the 0 for patients not suffering the symptom